Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Clinical trials and evidence)

Innovation 'Elevator Pitch':
Active+: Reducing demand for Outpatient Serivces with proactive education, activation and exercise using connected devices to self-care.
Overview of Innovation:
Active+ is an effective, evidence-based exercise class, supported by self-care technology, education and training, in a peer-to-peer supported programme developed in Huntingdonshire. The programme supports falls prevention (strength/ balance), cardiac, cancer and pulmonary rehabilitation.

In May 2017, the Activ8rlives Active+ feasibility began with cardiac rehabilitation classes inte-grating remote monitoring technology. These are being extended to people with coronary heart disease risk factors, cancer and chronic obstructive pulmonary disorder.

Active+ is a collaboration between local technology provider Aseptika Limited (Activ8rlives), Huntingdonshire District Council (HDC) Active Lifestyles, Papworth Hospital NHS Foundation Trust, Huntingdonshire Community Cancer Network (HCCN), Hunts Breathe for Life and Eastern Academic Health Science Network (EAHSN).

​See Maggie's story (Cardiac Rehabilitiation) here
​See Colin's story (Cancer Rehabilition - living with prostate cancer) here.

For further information contact
Kevin A. Auton, PhD, Managing Director, Aseptika Limited kevin.auton@aseptika.com www.activ8rlvies.com
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Active+ fills the gap between existing health and care services, with the intention of improving health outcomes and minimising expensive interventions resulting from deterioration. Evidence4 shows that people who are more activated are more likely to adopt positive behaviours and have clinical indicators within a normal range, resulting in 8% lower costs than those less activated in the fist year of support and 21% less in the second year.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Patients are educated and supported to interpret the data to enable improved understanding of their health status.
  1. Prevent unnecessary admissions as patients have access to 24/7 the COPD rapid response team as soon as there is any health deterioration for treatment to prevent unnecessary admission into hospital. The collected data is currently being analysed by Knowsley Respiratory Community Team.
  2. Technology improves patient’s confidence in managing their COPD. For patients who experience frequent infections and disease exacerbation, this can be a lifeline. In Liverpool 90% of participants would recommend to Friends and Family. 60% would be prepared to make a financial contribution of £300 to support costs.
Current and planned activity: 
Looking for Clinical Champions in Secondary Care seeking to reduce the Outpatient Workload by creation of an alternative step-down care pathway while still retaining connection with patients in a light-touch mode.
What is the intellectual property status of your innovation?:
IP owned by Aseptika Ltd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Kevin A. Auton 12/01/2017 - 12:55 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Optimised Equivalent® to best performing & highest volume branded orthopaedic implants (>1,000,000 patients), coupled with significant savings. Equivalent manufacture, materials, tolerances & sizes, along with operational technique & instrumentation.
Overview of Innovation:
The UK is the first country in the world to benefit from applying the principle of generics to orthopaedic products. Generic medicines have been a core part of the NHS since the 1980s, offering the same clinical outcomes for patients as originator drugs and now contributing over £12 billion in savings every year that can be reinvested into the health service (1)

With >66,000 NHS hip replacement operations performed every year (2) switching to generic hip implants from the current market leaders, the NHS could save up to £120 million by 2020 - enough to fund over 1,400 junior nurses every year (2,3,4)

This is well-timed following Lord Carter’s Review, which found that large efficiency savings can be made by all NHS hospitals – notably in orthopaedics. Some of these savings can be made by reducing the current variation in patient outcomes (5)
 
Evidence from over 1,000,000 hip replacement operations in published registry data shows that some of the most widely used devices with the lowest possible revision rates can be provided at a significantly reduced cost due to patent expiration. Orthimo have produced Optimised Equivalent® implants to the branded versions, providing significant cost savings without compromising patient outcomes.

The manufacturing of the Optimised Equivalent® implants are by well established suppliers with many decades of experience in manufacturing orthopaedic implants for the large Orthopaedic companies, further strengthening the equivalence value proposition.  Both the surgical instruments and techniques are also equivalent.

As a further indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent® implants through a forward buying fund, which can be obtained via NHS Supply Chain.
 
At a time of unprecedented cost pressures on Healthcare systems worldwide, Optimised Equivalent® implants make a valuable contribution towards maintaining high quality hip replacement services within the limited resources available.

This means patients receive the best clinical outcomes at significant cost savings for hospitals.

http://www.odep.org.uk/Product.aspx?pid=2301

http://www.beyondcompliance.org.uk/product.aspx?pid=2301

https://my.supplychain.nhs.uk/Catalogue/product/fjh10279

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence
Benefit to NHS:
Orthimo provide equivalents of the best performing and most commonly used branded orthopaedic implants, as proven by registry data of over 1,000,000 patients. Similarly to generic pharmaceuticals, which the NHS already takes advantage of, Orthimo products come with significant savings of 30-60%. This could save the NHS up to £120million by 2020.
 
These can be provided with minimal disruption to services and procedures due to the sizes, instrumentation and operative technique being equivalent to the most commonly used branded products. They are available through a simple and transparent pricing structure, which can be via the Total Orthopaedic Solutions, Chester or NHS Supply Chain frameworks.
 
As an indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent ® implants through a forward buying fund, which can be obtained via NHS Supply Chain. With most Trusts using one or more of the branded reference components, a transition to make savings has never been easier.
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
Orthimo provides generic versions of the best performing hip implants, this means patients in the West Midland area can receive the best clinical outcomes at significant savings to the hospital and trusts in the region. 
 
In the West Midland approximately 6,000 hip replacements are performed per annum. If, at a conservative estimation, these cost £700 each on average, generic hip implants could save the West Midland area over £1.5m per annum.
Current and planned activity: 
With Optimised Equivalents being available via all Orthopaedic frameworks, Orthimo are seeking Surgeons to conduct small volume evaluations or for Trusts to allocate a proportion of their hip work.

As with the generic pharmaceutical industry, there is a need to establish a policy change to ensure the responsible and active use of generic orthopaedic implants.
  • Procurement: -  Require sales and marketing to Trauma & Orthopaedics departments and procurement
  • Evaluation - Seek ‘Beyond Compliance’ service evaluation centres for uncemented range
  • Adoption:- Seek Hospitals/Surgeons to conduct small volumes of procedures
  • New Product Development:- Require experts to propose and support development of new products
What is the intellectual property status of your innovation?:
All IP resides with Orthimo.

Orthimo holds BSI CE Mark for all implants.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Optimised Equivalents use the most common and best performing branded reference products. These are used in most Trusts across the country, and so an introduction will have minimal disruption. We use the same sub-contracted manufacturers and logistics which the large companies use, and so supply can be scaled rapidly. 
Measures:
Our products are being used via the Beyond Compliance process. This data will be used to apply for successive ODEP ratings when the criteria are acheived. 
Adoption target:
We are looking for Trusts to use Optimised Equivalents for their low risk, common primary elective total hip replacement procedures. It has been estimated that this would be in excess of 60% of cases. 
Read more
Hide details
Oliver Wylie 09/01/2017 - 17:16 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
65m urine specimens analysed annually in the UK breaks down to 250,000 every working day, of which 45,000 will be unreliable. This means 45,000 patients daily who will not be treated for urine-based infections. Peezy Midstream means they can.
Overview of Innovation:
Peezy Midstream can save the NHS £30m in reduced retesting of the most common diagnostic procedure.

It is a simple but innovative device that automatically captures clean-catch urine from men, women and children (from toddler age). It is especially valuable for the elderly and pregnant women for whom accurate urine screening is essential.

The average national mixed growth rate reaches from 0.38% to over 70%; the average is 18% - that's nearly 1 in 5 patients who will not receive accurate right-first-time treatment from their urine specimen.

Peezy Midstream reduces mixed growth rates to 1.5%, which means many more patients will be treated right-first-time, saving the NHS as a whole over £30m in direct retest costs and over £1bn indirectly through saving repeat staff and resource time.

Peezy Midstream captures urine specimens hygienically - it prevents spills and splashing, improving infection control in healthcare settings. It can be held by the tube if help needs to be given - the assistant does not risk becoming soiled either.

Dignity is implicit; easy Peezy is comfortable, quick and removes the need to start-stop-start when giving a midstream urine specimen.

There is no down-side to using Peezy Midstream. It saves lives, saves time and money and reduces unnecessary broad spectrum anitbiotic prescribing. Peezy is poised to make novel cancer urine tests more efficient too.

Each Peezy kit costs just 87p on the NHSSC; use ten for every retest. Available on the NHS Supply Chain and on the UK Drug Tariff - growing in popularity with midwives and care givers to the elderly.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Peezy Midstream delivers huge cost and efficiency savings plus clinical benefits:

(See attached WM mixed growth data and separate cost savings model)
  • Reduction of average West Midlands mixed growth rate of 17.5% to 1.5%
  • West Midlands direct savings of £307,798
  • West Midlands indirect savings of £12,339,337 (see attached WM cost savings model)
  • reduced urine specimen mixed growth from West Midlands average  to 1.5%
  • right-first-time urine analysis, diagnosis and treatment - don't see the same patient twice for the same problem
  • delivers specimen into 10ml tube that fits most automated laboratory urine analysers (no decanting in lab)
  • no soiling, dry tube, clean toilets: more hygienic for healthcare professionals
  • targeted prescribing, reducing need for broad spectrum antibiotics
  • improved infection control: no spills or splashing of urine
  • works equally for men, women and children (from toddler age)
  • excellent for pregnant women where antenatal screening must be super-accurate; they don't have to see the funnel is in place - they can feel it
  • antenatal screening accuracy for maternal diabetes, pre-eclampsia
  • excellent for the elderly prone to UTI, which can affect both wellbeing and behaviour
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
  • West Midland Patient Savings of £90 (please see attached WM cost savings model, Patient Savings tab)
  • Accurate urine specimens mean prompt, accurate diagnoses
  • Patients will no longer need to visit their GP more than once for urine-related illnesses
  • They will receive the correct, targeted antibiotic, helping the fight against anitmicrobial resistance, encouraged by over prescribing of broad spectrums
Current and planned activity: 
  • Peezy Midstream is on the NHS Supply Chain at 87p (Peezy, tube, genital wipe)
  • It is approved by NHS Prescription Services and on the Drug Tariff for prescribing
  • Quality Improvement Audit at Barts (London) shows reduction in mixed growth from 17.5% to 1.5%
  • Quantative clinical study results pending from Stanford Medical School
  • Peezy currently part of MS Rapid Diagnostics Pilot, London
  • Prescribing growing amongst antenatal population
  • In use within some NHS departments: urology, outpatients, pre-admission, antenatal, A&E, Ambulance Services
What is the intellectual property status of your innovation?:
Patent and trademark granted:
  • UK
  • USA
  • Europe
  • China
  • Australisa
  • Asia
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Easy; Peezy is available through the NHS Supply Chain
Forte Medical is happy to attend your location and brief staff on usage and instructions if necessary
Measures:
Reduced mixed growth
Reduced retesting
Reduced repeat appointments
Cost and efficiency savings
Adoption target:
6 months
Read more
Hide details
Giovanna Forte 09/11/2016 - 15:50 Detailed Submission 1 comment
4.7
3
Votes
-99999
Innovation 'Elevator Pitch':

Converting Clinical lab based Xanthochromia procedure into Near Patient testing/Point of Care Procedure using pocket sized spectrometer.

Overview of Innovation:

I am thinking of converting Xanthochromia lab based spectrophotometry procedure (SAH/fatal accidents/Head injuries) into Point-of-care/Near patient testing (POCT) procedure. A small pocket sized spectrometer is going to come soon in the market.

The device is a molecular sensor with cloud based database. The company offers developmental tools to build the database, by scanning  every material that exists in this world..from paracetamol to material science. 

Converting this to POCT offer some advantages: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses themselves without much technical comptency can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Current and planned activity: 

Contacted the chief technology officer of the Company (Consumer physics) awaiting response for modifying the device into POCT medical diagnostic device. If green signal given may discuss with NHS trust and start the joint development/clinical trial/evaluation/validation/verification using NHS trust as base 

What is the intellectual property status of your innovation?:

N/A

Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
GANAESH 27/10/2016 - 03:21 Publish Login or Register to post comments
4
1
Votes
-99999
Innovation 'Elevator Pitch':

The Recipe for Workforce Planning is an easy-to-use online tool driven by a dynamic process map.The Recipe is a repository for best practice and facilitates peer support through a discussion forum.

Overview of Innovation:

The Recipe for Workforce Planning is an easy-to-use online tool driven by a dynamic process map; users click on each stage of the process to access resources and view the activities needed to complete that stage. The Recipe is a repository for best practice and facilitates peer support through a discussion forum.

This unique resource is the first of its kind, developed by Health Education England working across the West Midlands, and is being shared for use across Health Education England.

The Recipe process map, created in collaboration with workforce planners across the West Midlands, shows the stages that should be completed in order to create a good workforce plan:
 
Users can click on a stage to open a Stage Page showing:

  • Ingredients - documents and resources needed to complete that stage which users can download.
  • Method - activities necessary to complete that stage with assigned roles.
  • Hints and Tips – any useful advice or intelligence that will support the completion of the stage

The Recipe also includes:
 
What should I be cooking this month?
Each stage in the Recipe has a date range during which that activity should be completed.  Users will be able to see the stages within the Recipe which are currently ‘active’ at the time they visit the site.
 
Roles and Responsibilities
Each of the activities within a stage has an assigned role e.g. Workforce Planner, Finance Lead.  Users will be able to sort and filter the site to view only the stages and activities relevant to their role.
 
Discussion forum
The Recipe has a discussion area where planners can share ideas and ask questions or queries.  
 
Cookbooks
Users can select their favourite resources from the site (Word, Excel, PDF documents) and download these into a pack, or Cookbook.  There are also readymade Cookbooks for particular users and scenarios e.g. Workforce Planning for Beginners, Meeting with the Executive Team, Workforce Planning for Commissioners.
 
Links and Resources
The resources – or Ingredients – available to users for each stage are added to and updated as new resources become available.  However, there may be useful resources, reports, articles or links that are not relevant to a particular stage but may be of interest to workforce planners.  These are available on the Links and Resources page that will include an archive of all the resources on the site.
 
The Recipe also includes a search function and an interactive glossary. 

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Education, training and future workforce / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:

Provides an easy-to-use online tool driven by a dynamic process map, demonstrating what good workforce planning looks like. This unique resource is the first of its kind and can be used in any clinical or non clinical setting when looking to effectively workforce plan.

Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:

Provides an easy-to-use online tool driven by a dynamic process map, demonstrating what good workforce planning looks like. This unique resource is the first of its kind and can be used in any clinical or non clinical setting when looking to effectively workforce plan. This resource was developed by the West Midlands and includes templates and resources which are currently being used across the region.

Current and planned activity: 

We have launched this resource nationally and are actively promoting this resource across the West Midlands, incorporating any feedback we receive.

For more information or to access the Recipe for Workforce Planning click here

What is the intellectual property status of your innovation?:

Health Education England.

Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Sarah Chamberlain 25/10/2016 - 11:44 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Incredible amounts of expensive drugs are thrown away by pharmaceuticals companies, health trusts & GP surgeries due to refrigeration problems. Everyware technology enables remote data monitoring & intervention for pharmaceutical & food storage
Overview of Innovation:
The problem. Correct handling and storage of drugs and medicines is critical in ensuring that they remain functional and safe to use. Regular monitoring and data capture highlights trends and issues not evident from manual record keeping. Over weekends and during holiday periods readings may not be recorded. Failure of a refrigerator or break in power supply could render contents unusable or remain undetected
 
EveryWare has developed an intelligent software platform with smart sensors, integrated and modular, in conjunction with clinicians to tackle this major problem. Local devices monitor a range of parameters, including ambient temperature, pressure and humidity; together with refrigeration temperatures at different levels within each unit
 
Local and remote alerts can be triggered when your own defined rules are breached. Alerts may be visual and audible in a monitored location with users receiving direct notifications via email, SMS and other channels. Data is visualized and accessible on computers, tablets and smartphones
 
Testimonial
Clinical bodies and Trusts’ guidelines require regular monitoring of critical storage temperatures. Legislation requires that records are kept and this is often a manual task with readings taken at up to 24 hour intervals
 
Successful trials yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7

Differences between types of refrigerator become evident. Recovery time following prolonged periods of access can expose the contents to raised temperatures for longer; trend data clearly demonstrates the effects of daily routines and identifies opportunities for training that will improve the safe storage and dispensing of critical medicines
 
EveryWare’s unique modular system means that the unit cost of the sensors is low. All other costs are capped, so no need to worry about data rates and variable costs. Annual cost of the system is a fraction of the cost of the assets or processes being monitored. System is designed from the ground up to be completely user-configurable to suit local and business requirements. Security is paramount; all cloud systems and data are network-isolated, multiple-passkey protected with encrypted communications.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Compliant drug storage
There is a legislative requirement to store critical medicines within specified parameters. Moreover, it is imperative that safe storage can be demonstrated and that only safe products are used.
 
Equally, any fault or disruption to the storage infrastructure doesn’t automatically render the products beyond safe use. Smart monitoring, reporting and validation afford peace of mind. Efficacy of the drugs can be evidenced and detect abnormal patterns of behaviour or access issues e.g. refrigerator door left open.
 
Broad clinical guidelines indicate that regular, period monitoring by technicians will suffice; often once every 24 hours and often not during weekends and holiday periods.
 
There are several risks with this approach that can render expensive drugs ineffective and worse still, fail to deliver the anticipated results. A power outage in the early hours or over a weekend may be masked by a reinstatement long before working hours. The damage may already be done if excessive temperatures have been realised.
 
The solution is to introduce smart monitoring with remote data logging and alerts. Continuous, electronic monitoring not only captures specific events 24/7 and raise alarms but provides valuable trend data. Battery backup will buffer mains failure without disruption to the monitoring or connectivity. Real time monitoring has clearly shown systematic issues occur out of working hours and variations within specific refrigerated facilities. Clinical practices will also affect the storage conditions; a feature that is evident from trend data. The effects of prolonged loading and unloading with the refrigerator open shows the impact upon refrigeration temperatures and the extended recovery time to achieve safe storage temperatures when eventually closed. Access to the refrigerators out of prescribed hours may also raise an alert if there is a security concern.
 
EveryWare has installed local monitoring systems in hospitals and clinical environments that are capable of tracking a range of critical conditions. Not just in refrigeration units but ambient conditions in key locations may be monitored through a common network. Within treatment, theatre, storage or living areas the network of wireless devices can track temperature, relative humidity and pressure along with other factors such as controlled access and refrigeration performance.
 
In homes EveryWare could be used with ambient and movement sensors to detect risk of hypothermia or falls.
 
Initial Review Rating
4.60 (2 ratings)
Benefit to WM population:
Overall benefits summary
Installations of the system have already demonstrated potential savings in recent trials.
  • Money saved by GP surgeries and health trusts through proper refrigeration of medicines
  • Money saved by pharmaceuticals companies through proper refrigeration 
  • Money saved by pharmaceuticals companies by not having to pre-emptively over-produce product to compensate for GP and trust wastage
  • Quality of patient care increases as a result of cost savings throughout the medicine supply chain
  • Meets strict legislative requirements ((strict environmental monitoring protocols are now required by CQC. Failure to comply requires drugs be destroyed at very high cost).
  • Modular (easy to add on additional ambient sensors, movements detectors etc)
  • Quick to install and upgrade
  • Predictive analytics software enables custom ‘rules based’ alerts to be created easily
  • Monitor multiple installations and multiple sensors from a single location (Dashboard)
     
Quality control
  • Constant monitoring of refrigeration and the ability to react instantly minimises the amount of wastage caused by medicine being spoiled by high temperatures. The unique modular design enables additional sensors to be quickly integrated. Predictive analytics software enables custom ‘rules based’ alerts and monitoring protocols to be easily created and monitored.
Legislation
  • The easy monitoring of temperatures makes it much easier to comply with the strict legislation imposed by health bodies such as the MHRA and CQC.
     
GP Surgeries
  • Surgeries and trusts are able to monitor the temperature of their drugs in the refrigerator and react instantly should parameters be broken.
     
Patient care
  • The cost savings made by reducing wastage can be channelled back into the healthcare system, improving overall patient care.
For more information see: http://www.everyware.uk.com/products/21st-century-drug-monitoring
Current and planned activity: 
Current Activity
Successful trials have been conducted with SWFT Clinical Services Ltd (a subsidiary of the South Warwickshire NHS Foundation Trust) which yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them.
 
Positive actions were taken to improve the effectiveness and avoid potential problems that might have occurred. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7.
 
We have recently entered discussions with GP practice in Norfolk in response to CQC’s strict environmental monitoring requirement for drug storage.

Planned Activity
  • We would welcome NHS input in our systems design and further development
  • We wish to increase awareness within GP and CCGs
  • We are seeking additional trial sites
What is the intellectual property status of your innovation?:
All IP resides with the company
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Nigel Maris 18/10/2016 - 10:42 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Tipsim® is a completely new product producing long lasting improvements in sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma or other neuro diseases e.g. Complex Regional Pain Syndrome.
Overview of Innovation:
Tip-stimulation with Tipstim® facilitates long-lasting therapy procedures. By sensory stimulation of the finger tips, Tipstim® drives plasticity processes in cerebral areas involved in the activation of the hand and fingers. Specially designed stimulation patterns – developed over many years of research & trials at the Institute for Neuroinformatics at the Ruhr University Bochum – are generated by a small, portable electronic pulse generator and applied directly to the finger tips via a completely new and highly-sophisticated therapy glove. The Tipstim glove® is the first product of its kind to utilise a new advanced medically approved conductive and biocompatible textile.
 
The therapy is completely painless, without side-effects and very easy to apply. The patient simply pulls over the glove, connects it to the pulse generator and starts the therapy session once a day for 1 hour. The therapy does not demand any special attention from the patient. Due to the small size of the pulse generator, the therapy can easily be integrated into everyday life and home. In principle, therapy can be applied everywhere, even when out walking.


 The proven efficiency of Tipstim® results from stimulation pattern specially designed for most effective enforcement of neuroplasticity processes. Clinical studies show that these special patterns produce cerebral changes which lead to persistent improvement of a patient’s sensorimotor abilities. This especially true with sensory and proprioceptive deficits which have shown a greater recovery than with standard rehabilitation therapy alone
 
Studies have shown that sensory stimulation drives plastic processes in the brain areas activated by the stimulation. This induces reorganisation in and around those brain areas that became dysfunctional by stroke or other brain injuries. This reorganization facilitates reactivation of cortical tissue that has preserved some functionality. The resulting remodelling of cortical circuits then mediates functional recovery.
 
Tipstim® is a clinically tested and CE approved product. The efficacy & safety of Tipstim® therapy has been proven in rigorous clinical trials.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Person centred care
Benefit to NHS:
Stroke is the UK’s third biggest killer.
 
First-time incidence of stroke occurs almost 17 million times a year worldwide; one every two seconds. Stroke is one of the largest causes of disability – half of all stroke survivors have a disability.
 
In the UK there are 152,000 recorded incidences of stroke a year and currently over 1.2 million stroke survivors. The economic costs of stroke in the UK from a societal perspective totals around £9 billion a year (Source: State of the Nation Stroke statistics - January 2016). The average cost of care (acute & rehabilitation) per stroke patient is currently £23,315 (National Audit Office. Progress in improving stroke care..., (February 2010). NAO Report (HC 291 2009-2010))
 
Over a third of stroke survivors in the UK are dependent on others.
 
Tipstim® is a completely new product to improve sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma and other neurological diseases such as Complex Regional Pain Syndrome.
 
Tipstim® comprises a small, battery powered electronic pulse generator unit and a close fitting glove that delivers the neurostimulation at the finger tips. Due to the compact size of the pulse generator, the therapy can easily be integrated into everyday life. In principle, therapy can be delivered everywhere, even during walking or when reading or watching television.
 
Clinical trials have demonstrated that the stimulation provided by Tipstim®  demonstrates a persistant reactivation of affected brain areas responsible to sensory and motor control of the hand and fingers. Moreover, balancing processes in adjacent non-affected brain areas are promoted.
The result is a substantially improved sense of touch as well as an improved mobility of the concerned hand.
 
The sensory & functional improvements resulting from Tipstim® neurostimulation have been demonstrated to last longer than for traditional therapy alone.
 
The Tipstim® is self contained and can easily be used by the patient in their own home. This reduces the frequency of hospital / clinic visits, frees up therapist time and would enable more patients to be treated than is currently possible.
 
Furthermore, the sensory and functional improvements resulting from the Tipstim® therapy will increase the patient’s ability to carry out task of daily living and will therefore increase their independence, thus reducing the need for additional care and support – with resultant manpower and monetary savings.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands has the highest mortality for stroke in England in people over 65.
 
The region’s ethnic diversity and socioeconomic status also reflects in a higher than average incidence of strokes as people of black and South Asian origin are at double the risk of stroke as are those living in the most economically deprived areas of the UK (West Midlands has 28.1% of its population in the most deprived national quintile)
 
These statistics demonstrate that the demand for stroke rehabilitation services will be higher than the national average and therefore the opportunity to make a significant impact will be greater for therapies such as Tipstim®.
 
The region also has the lowest percentage of patients returning to their usual place of residence, and this is statistically significantly lower than the England average. Improved  independence and post stroke rehabilitation would help to address this and enable people to return to their own homes and live independently.
Current and planned activity: 
We are currently undertaking a pilot multicentre clinical trial of Tipstim® at the Countess of Chester NHS Foundation Trust, Chester.
We would welcome the opportunity to engage with the West Midland’s Stroke rehabilitation communities to raise awareness of our Tipstim®.
In addition, we wish to explore support for business model development and delivery strategies for NHS adoption and or private procurement.

We are also very interested in conducting a cost benefits analysis health economics study of therapeutic intervention with Tipstim®.
What is the intellectual property status of your innovation?:
Tipstim® is protected via granted patents and registered design rights held by the parent company.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Bharat Vadukul 21/09/2016 - 14:15 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Flo-Tone CR is a tool helping patients acquire good Maintenance & Technique in using Pressurised Inhalers, teaching how to Inhale SLOWLY and STEADILY. Inhaler Technique Skills are important and a major theme in BTS, GINA and NICE guidance.
Overview of Innovation:
Flo-Tone MDI (also known as Flo-Tone CR) uses a ‘Positive’ Coaching Whistle to help patients learn to inhale SLOWLY and STEADILY. Whistle Signal is a prompt for the canister to be pressed releasing the medication & the duration of the Whistle helps the professional to coach the patient towards correct use.
Pressurised inhaler mouthpieces come in a variety of shapes, accordingly Flo-Tone was originally produced in ‘Circular’ & ‘Regular’ Models. A new improved Flo-Tone CR now fits all mouthpiece shapes by fitting inside the pMDI mouthpiece. The new design ensures all pMDIs produce a whistle at the same flow rate, helping standardise technique.
Studies have been conducted with the new Flo-Tone to ensure that it delivers the full dose. The first study detailing the development of the improvement & its performance was presented at BTS 2015 & subsequently at DDL26.
Available on prescription, the improved Flo-Tone CR can be used with a pMDI simulator (Trainhaler) for training & with the Patient pMDI. It incorporates a cap so that it can be left in situ on the Inhaler. It also includes a rim on the mouthpiece to help patients get their teeth out of the way of the aerosol spray.
We have tested Flo-Tone CR with a variety of inhaled medications (Flutiform, Clenil, Ventolin, QVAR and Sirdupla) – in each case the respirable dose (ie that part that reaches the lungs) delivered for the medication plus Flo-Tone closely matched that of the device alone & in each case unwanted throat deposition was reduced.
•Flo-Tone CR controls the resistance of the pMDI, thereby standardising the flow rate at which  
  Flo-Tone CR whistles
•Provide inhalation & coordination guidance
•Sounds (20-25 L/min)
•Drug delivery improvement = Therapeutic Improvement
•Less throat deposition – potentially less unwanted Throat Side-Effects
•Better control - less breakthrough – less SABA needed
•Better control – less hospitalisation 


• Spacer & Mask with anti-Microbial & anti-static properties
Collapsible – helps with storage & travel
• Visible valve movement - see that the drug is being Inhaled
• Suitable for adults & children
• Performance validated with pMDI’s
• Accepts all pMDI’s available
• Available with small & medium mask


• Ideal for emergency services use, schools & within General Practice & Hospitals for reversibility testing
• Single patient use
• Economical & environmentally friendly
• Performance validated with pMDI’s
• Available in bulk pack 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There have been many papers published, detailing the misuse of pMDI among patients;
Clement Clarke International have used their expertise to concentrate on this area of products. This
has led to the introduction of the ‘Inhaler Technique Training’ range. Each device is targeted at the
training of inhalation technique, guiding patients to inhale at the correct flow rate for pMDI use.
 
Inhaler technique errors occur in the hands of patients and healthcare professionals. It has been
demonstrated that the majority of healthcare professionals cannot demonstrate correct inhaler use
to their patients. It is not therefore surprising that patients are mostly unable to demonstrate good
inhaler technique. The consequences are significant; patients take higher doses to compensate for
lack of efficacy from medication lost through poor technique, this results in poorer control,
hospitalisation and increased healthcare costs.

The Clement Clarke ‘Inhaler Technique Training’ range delivers more reliable, more effective and patient friendly usage of medication and treatment (therapy) delivery.
Benefits summary
  • Patient friendly medication management and use
  • More effective and accurate delivery of medication to lungs
  • Reduced number of hospital admissions
  • Reduced number of un-planned clinical interventions
  • Reduced associated therapeutic costs
  • Improved patients’ health and quality of life
  • Available on the National Drug Tariff
  • Low cost devices
  • Available for immediate use
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
The West Midlands region provides a great opportunity for rapid realisation of the benefits of improved inhaler training from a clinical, economic and patients’ quality of life perspectives.

All the required products and training materials are currently available for instant deployment and would offer significant benefits to those GP practices or secondary care providers willing to challenge existing ineffective training and delivery mechanisms and who would act as either the Regional or National adoption lead.
 
A comprehensive breakdown of the tools and devices required for a GP practice has been provided in an attached document (Essential Requirements for GP Practice Inhaler Training Kits).
Current and planned activity: 
Current NHS activity
Key areas of Contact are Lung Function & Respiratory Medicine which include Respiratory Physiologists & Respiratory Nurses both in Adults & Paediatrics.
 
Flo-Tone has been adopted by Wolverhampton CCG.

Planned/required activity
As a Manufacturer, Clement Clarke undertakes an extensive R&D program and also undertakes On-Site Clinical Trials with GP Practice & Secondary Care.
However, research and trials support partners would be welcomed to further develop the evidence base demonstrating the benefits of improved staff training with associated patient benefits.
In addition, Health Economic studies would also be welcomed to quantify the medication and admission cost savings that would be achieved. This would supplement the Isle of Wight study and include a wider geographical and ethnic / demographic patient cohort.
What is the intellectual property status of your innovation?:
All intellectual Property for devices and training is held by Clement Clarke International
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Anthony Silvio Philips 31/08/2016 - 12:46 Publish Login or Register to post comments
4
1
Votes
-99999
Innovation 'Elevator Pitch':
Disruptive technology prevents Left Ventricular remodelling post MI & promotes tissue regeneration. Product result of £10M EU investment & 5 years R&D. Biocompatible & Biodegradable product demonstrated pre-clinically in wide range of animal model.
Overview of Innovation:
Cardiac patch is a scaffold structure compatible with in-vitro cell seeding & cell culture used as a vector for cellular therapy in addition to structural support. Numerous applications include curettage & cardiac transmural use in addition to soft tissue engineering such as hernias & vein repair. Scaffold composition comprises poly(caprolactone), alginate & composites thereof with natural polymers such as chitosan & alginate fibroin decorated with a synthetic peptidic hydrogel. Porosity can be tailored with pore range of 10-250µm, permitting angiogenesis and cell seeding. Although the biomaterial can be used independently as a medical device for prosthetic applications, its main tissue engineering function is to enhance cell attachment, growth & differentiation. An extension of the device is its functionalisation with cell signalling agent capacity providing the scaffold with extracellular matrix like micro-environment. Polymeric self-assembled structure is composed of but not limited to peptidic or polyurethane amphiphiles & can be loaded with chemical & biological cues covalently or via entrapment.

To initiate regeneration, the biomaterial must encourage in-vivo revascularisation & promote integration with host tissue. Concurrently, it should biodegrade at the same rate that newly formed tissue replaces it, being removed from the body by natural metabolic pathways without toxic by-products.

The patch provides both a temporary mechanical support to the infarcted myocardium preventing further damage to the surrounding tissue and prevents aneurism formation in the infarcted area whilst regeneration take place

Myocardial infarct treatment
Device can be used for in-vitro & in-vivo applications. Both parts of the device can be loaded with cell signalling agents or drugs for research & clinical use. Fibre based secondary drug delivery structure allows multiple growth factor/drug release with different release profiles as a direct tool for gel functionalisation with patient blood components in-vivo.

The system’s mechanical properties match the tissue it replaces. 3D hydrophobic/hydrophilic scaffold provides mechanical support to a gel that acts as scaffold plasticizer & provides an hydrophilic interface with host environment. The gel can also collect cell signalling agents from its immediate environment. The electrospun fibre based drug delivery system can additionally be used as a complementary tool to the gel for loading with cell signalling agents, drugs etc
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
The leading global trend in interventional cardiology is to adopt less invasive technologies, reducing patient recovery time & improving quality of life.
 
PeptiGelDesign Cardiac Patch treats myocardial infarction (MI). Current treatments are based on medication &/or organ transplantation. Approx. 4,600 heart transplants are carried out pa in Europe & the USA (1,900 EU). Even with current medical management, over 1/3 of acute heart attacks are fatal. Rehabilitation levels following MI are variable with major damage unable to be fully healed. Current treatments to prevent tissue damage post MI include thrombolytic agents. These drugs have greatly reduced morbidity & mortality, but must be administered within a short interval following MI to be effective. Cardiac catheterization & Angioplasty have proven effective in restoring blood flow, but cannot reverse tissue damage. Transplantation is complicated surgery, severely limited by lack of donor organs.


Advantages of cardiac patch over current treatment regimes:
 
• Complements established therapies restoring damaged cardiac muscle ensuring improved contractility function & eliminating CHD related early mortality. Following non-lethal MI current treatments effectively restore blood flow, but cannot reverse tissue damage leading to limited rehabilitation & QoL
 
• Restoration of cardiac function drastically reduces re-infarction rates & need for subsequent interventions.


• Demonstrably increases life expectancy post MI. In cases of CABG (bypass), 5-year mortality rate for target population (patients with abnormal Left Ventricular (LV) function typically caused by MI) is 16.5% vs a mortality rate for patients with normal LV function of 8.5% (50% improvement). We could expect the cardiac patch to reduce mortality of patients undergoing MI to the level of those with normal LV function due to recovery of infarcted heart. Similarly, 5-year mortality rate of 80% for post MI patients undergoing an interventional procedure decreases to 40% - the mortality rate for patients undergoing the same procedure but with normal LV function.


• By enabling recovery of the heart muscle patients improve their NYHA class, suffer less Angina Pectoris, reduced incidence  of re-infarction, need less medication & hospitalization & improve QoL. NB: 10 years post CABG intervention, overall survival rate is 69% vs overall event free rate of 41%, suggesting that a significant portion of patients are surviving but with a fairly low QoL
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
In addition to the many benefits to the wider NHS outlined above, there are specific regional benefits accruing from the adoption of this medical device and treatment regime.
 
The high incidence of Chronic Heart Disease and the costly rehabilitation of patients post heart attack is a recognised priority within the West Midlands population.
 
The cardiac patch offers a minimally invasive and rapidly deployable intervention that will significantly improve the quality of life for patients surviving Myocardial Infarction.
 
In addition, the cost and time savings to the NHS and social care through improving patient outcomes, reduced number of transplants and greater quality of life and increased independence for patients post MI will be significant.
Current and planned activity: 
(See attached document for more information)
PeptiGelDesign is currently engaged with the Liverpool Heart and Chest Hospital.

Wish to partner with NHS and NHS Research Organisations on clinical trials for cardiac patch development.

As our primary target market is the UK, we wish to raise profile within the NHS and work with its stakeholders to bring our technology to the market and ultimately to the patient.
  • Explore if entitled to an  Investigational Device Exemption (IDE) ?
  • Identify sources of funding to support PeptiGelDesign pursuing the further validation.
  • Procurement/Adoption: -  Require routes to GP sales - marketing products to CCGs
  • Evaluation/Validation/Clinical Trial - Need to gain additional validation - seeking a trial centre.
  • Concept Development - This is planned development work but seeking NHS partnership/advice.
Project Assistance required - The Company is interested in locating clinical/academic collaborators for new product development.
What is the intellectual property status of your innovation?:
PeptiGelDesign Ltd is licencing the WO2014044321 and finance patent granting process. Today, the patent has been accepted in USA, EU and Japan and will enter EU countries national phase in December 2016.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Guillaume Saint-Pierre 04/08/2016 - 10:33 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
LiverMultiScan is an FDA 510(k) cleared and CE marked MRI technology that provides a quantitative assessment of liver health, including fibroinflammatory disease, steatosis and iron, all in a non-contrast 5 minute scan.
Overview of Innovation:
Perspectum Diagnostics is a medical imaging company with an ISO 13485 compliant CoreLab. The company has developed novel imaging technology, LiverMultiScan, an MRI-based non-invasive tool that has attained CE-marking and FDA 510(k) clearance to aid the diagnosis of patients with chronic liver disease.
LiverMultiScan (and LiverMultiScan Discover for clinical trial use) can characterise liver tissue in three ways, providing accurate measurements of liver fat, hepatic iron content and fibro-inflammatory disease, using the proprietary Liver Inflammation and Fibrosis (LIF) score. The LIF score has been shown to stratify NAFLD and NASH patients (Pavlides, 2015), correlate with histological markers of inflammation and fibrosis (Banerjee, 2014), and most importantly, is the first imaging test to predict liver-related clinical outcomes (Pavlides, 2016). It is the only liver imaging technology included in the UK Biobank study, with 100,000 scans to be performed in the coming years (Kelly, 2015).
Available as a Quantitative Analysis Service (QAS), LiverMultiScan has been cleared as an imaging tool to aid the diagnosis of early liver disease. It offers a standardised and high-quality method for supporting Gastroenterology/Hepatology and Radiology departments in diagnosis and monitoring of the liver in clinical settings and studies, and has potential to streamline clinical management by compressing the diagnostic pathway. Perspectum is also supporting multiple international clinical trials with LiverMultiScan Discover.
  • Banerjee et al. (2014) Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 60:69-77.
  • Kelly et al. (2015) Predicted prevalence of NAFLD and NASH in a large population using non-invasive multiparametric MRI. AASLD 2015. Abstract ID: 931.
  • Pavlides et al. (2015) Multi-parametric magnetic resonance can accurately assess NAFLD histological disease severity; comparison with transient elastography. AASLD 2015. Abstract ID: 2190.
  • Pavlides et al. (2016) Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 64:308-315.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Patient and medicines safety
Benefit to NHS:
The utility of LiverMultiScan for assessing fibroinflammatory disease, steatosis and predicting clinical outcomes means it is well-positioned to reduce (and potentially remove) the need to perform invasive liver biopsies. It also facilitates longitudinal monitoring, which is near impossible with current sampling technology.
According to a recent NIHR HTA report, the cost of a liver biopsy is £956, but this can increase significantly with complications (clinically significant bleeding in 1.1 – 1.6%). For healthcare providers, liver biopsies are unappealing because of the attendant risk, financial cost, lack of reliability (as sampling only 0.002% of the liver volume), and uncertainty in interpretation. Nevertheless, primarily because there has not been a viable alternative, it is estimated that 650,000 liver biopsies are performed annually worldwide. 
There are substantial costs associated with managing patients with NAFLD, in particular for those patients progressing to NASH who are at significant risk of cirrhosis, HCC and liver failure. Although pharmacologic options are limited, there are numerous clinical trials ongoing.
Available treatment options increase (e.g., diet, surgery), outcomes improve and healthcare costs decrease the earlier those with, or at risk of, more advanced disease are identified. When combined with the rising incidence of NAFLD and NASH, the availability of a non-invasive test for accurately assessing fibroinflammatory disease, steatosis and predicting clinical outcomes, is vital.
A recent health economic study (submitted for publication) from the University of Birmingham concluded that LiverMultiScan is cost effective either as an adjunct to or replacement of Fibroscan in the diagnostic pathway of NAFLD. In addition, the utility of LiverMultiScan in reducing the proportion of patients with suspected NAFLD undergoing hospital consultations and/or liver biopsies is currently being evaluated in a large Europe-wide multicentre clinical trial (including the UK).
LiverMultiScan could allow:
  • A faster throughput and diagnostic analysis than conventional sampling – reducing patient lists and identifying those that need and do not need clinical intervention.
  • Regular monitoring of patients without painful invasive and potentially dangerous biopsies.
  • A less traumatic assessment of liver disease in children.
  • Assessment of liver health in other diseases (e.g., viral hepatitis, alcoholic liver disease)
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Liver disease is the fifth ‘big killer’ in England and Wales, after heart, cancer, stroke and respiratory disease (http://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease), with twice as many people dying from liver disease now compared to 1991.
In a European study, the healthcare costs for patients with NAFLD were 26% higher than for those without the disease (Baumeister, 2008). In the US, the direct costs of cirrhosis and chronic liver disease were estimated to by $2.5 billion, whereas indirect costs were estimated to be $10.6 billion (Ruhl, 2008).
Identifying those with, or at risk of, more advanced liver disease earlier increases treatment options available, reduces healthcare costs and improves outcomes. Benefitting both the NHS and wider West Midlands community.
This diagnostic test could also be used to aid the diagnosis and monitoring of liver disease in children, with a European clinical trial underway.
 
  • Baumeister et al. (2008) Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology. 134:85.
  • Ruhl et al. (2008) Costs of digestive disease. In The Burden of Digestive Disease in the United States. NIH Publication. pp 137-143.
Current and planned activity: 
LiverMultiScan currently in use at University Hospitals in Birmingham, Edinburgh, Oxford Southampton & Kings College London (KCL). Discussions with other NHS sites

Recent completion of large Innovate UK funded 2.5 year study at University Hospitals Birmingham & Edinburgh to develop & validate against liver biopsy

KCL is UK site for large EU multi-centre clinical trial to evaluate cost-effectiveness of LiverMultiScan in primary care pathway.

Patient study - 100 patients with history of liver disease receive LiverMultiScan, nearing completion with extremely +ve feedback

LiverMultiScan is only liver imaging technology in UK Biobank - 100,000 subjects to be imaged

Planned activity
West Midlands location of choice as:
  • Build on relationship with University of Birmingham following 2.5 yr study
  • West Midland’s considerable expertise in liver disease
  • Large patient cohort and trials infrastructure
  • Involve Children’s Hospital in study
  • Dr Banerjee, founder & CEO, visiting Hon. Consultant Hepatologist at UHB
What is the intellectual property status of your innovation?:
Perspectum holds or exclusively licenses 7 patent applications in the UK and other territories. To date, one has been granted in the UK (GB2497668).
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Matt Kelly 03/08/2016 - 12:07 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Exercise is the best medicine! The FABS Training Programme for older adult exercise tackles the consequences of physical inactivity as people age, increasing flexibility and mobility to improve everyday life.
Overview of Innovation:
We all understand the importance of moving more and sitting less when it comes to living a healthy and fulfilling life.  As we age this becomes even more important as our lives tend to become more sedentary which then leads to ‘inflammageing’ and many long-term health conditions.
 
The FABS Training Programme, developed by Move it or Lose it! in partnership with the Centre for Healthy Ageing Research at the University of Birmingham combines Flexibility, Aerobic, Balance and Strength exercises in every class, providing the four vital components of older adult fitness as per CMO guidelines.  This is made up of exercises that are safe, enjoyable, effective and accessible to everyone whatever their ability, and can be done seated or standing.
 
FABS classes ensure age or ability are no longer barriers to an active lifestyle. The aim of the class content is to increase strength and muscle density to reduce sarcopenia, improve balance to reduce the risk of falls, increase aerobic capacity to enable individuals to be more active and increase flexibility and mobility.
 
Via a blended approach of online learning and practical training, we train exercise instructors to become specialists in fitness for the over 60s enabling them to work with the fastest growing demographic in the UK. We have practical days scheduled for Birmingham, London, Manchester and Newcastle, with Edinburgh and Bristol coming in due course. 

The programme launched in March 2016 and has more than 90 instructors undertaking it to date. The aim is to train 1000 instructors who can deliver FABS classes within their local communities to combat social isolation, physical inactivity and cognitive decline and provide opportunities for fun and friendship for our fastest growing demographic; older people.  By training 1000 instructors the programme also generates wealth by creating 1000 small businesses with a licensing model similar to Zumba. 

Move it or Lose it! Exercise DVDs have been tried and tested.  The video stars in all our DVDs are not actors, but real people who have health conditions and mobility problems.  They have improved their lives through the Move it or Lose it! Exercise routines and they want to inspire others to do the same.
 
Move it or Lose it! DVDs are endorsed by Professor Janet Lord, Director of the MRC-ARUK Centre for Musculoskeletal Ageing Research at University of Birmingham as an ideal resource to aid active ageing.
 
http://www.moveitorloseit.co.uk/product-category/dvds/
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Person centred care
Benefit to NHS:
The consequences of physical inactivity as we age are not just associated with movement problems and ill health, but also social issues. This often leads to feeling isolated resulting in depression which can lead people into a downward spiral and consequently their loss of independence.
 
Professor Janet Lord, Director of the Centre for Healthy Ageing Research at University of Birmingham and advisor for the recent BBC One Programme ‘How to Stay Young’ says, “Exercise is the best medicine. We can reduce our risk of heart disease, some cancers, diabetes, obesity, arthritis and osteoporosis by up to 50% by simply getting people to move more and sit less.”
 
The programme has been recognised by the NHS and is currently involved in a trial with COPD patients for Birmingham Cross City CCG.  Patients will be monitored in aspects of biopsychosocial health with the aim of rolling out the sessions across the NHS.  From this 12 week COPD trial we will have a clear understanding of the benefits. We anticipate that general health will improve, in terms of physical function and mental wellbeing. This in turn will keep patients away from GP surgeries and hospitals for longer periods, thus reducing, or even preventing treatment costs. Education of self-management techniques will also contribute to this. 
 
The results will also be used to form the basis of a scientific research study which aims to reduce the effects of illnesses and long-term health conditions linked to inactivity in older people – such as diabetes and heart disease.
Online Discussion Rating
5.67 (3 ratings)
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The class members benefit from improvements in their health, reducing their risk of heart disease, some cancers, diabetes, obesity, arthritis and osteoporosis.  Move it or Lose it! assists with the development of practical solutions to improve levels of physical activity in older people.
 
This increase in activity has an economic impact for the NHS by improving physical and mental health, the cost of treatment needed for conditions associated with declines in health such as sarcopenia, osteoporosis and arthritis will be reduced. 
 
The FABS Training Programme provides job opportunities in the West Midlands. FABS Instructors will benefit from using an established brand in Move it or Lose it! that will help them to build their own business of exercise provision to the over 60s. 
Current and planned activity: 
We are currently engaged in a 12-week trial with the NHS, providing exercise as an intervention for COPD patients. This is taking place within the Birmingham Cross City CCG. 
 
We require academic support surrounding data evaluation to assist us to demonstrate the effectiveness of the exercise programme in terms of NHS financial savings and improved patient outcomes.
 
We are looking to expand our team of inspirational instructors and trainers so they can get everyone experiencing the fantastic benefits of Move it or Lose it! and FABS across the UK! Instructors receive continual support through The Exercise Network (T.E.N) aiding their knowledge and delivery. By building this network of exercise instructors Move it or Lose it! are helping older people and those with disabilities across the UK to get active to help them age well.
 
If you are passionate about helping older people to live life to the full then find out more here - http://www.moveitorloseit.co.uk/fabs/
 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Co-Authors:
Regional Scalability:
The FABS Training Programme is highly scalable due to eLearning platform, allowing many people to undertake the programme simultaneously. We can then offer multiple practical assessments dates at a central Birmingham location (as well as other venues nationally) for 20 instructors at a time. This would allow for rapid expansion of the programme in the West Midlands area.  The model that has been developed is a sustainable business model which ensures that income is generated from licensing, training and ongoing support.
Measures:
The aim of The FABS Training Programme innovation is to train 1000 specialist exercise instructors to the over 60s. The success of the innovation will be measured against achieving this goal.
The quality of The FABS Training Programme is measured through its recognition by industry regulators such as Active IQ and UK Active. This is also ensured via the company’s – Move it or Lose it – Quality Assurance Policy.
Move it or Lose it also has a Safety Policy and Equality and Diversity Policy to ensure the people training with us, the tutors and customers are kept safe and are treated with respect. 
Adoption target:
We would like to implement FABS classes within CCGs and be able to offer GPs with the opportunity for physical activity and social prescription within their own practice. Move it or Lose it would place FABS instructors into GP surgery’s increase social and activity levels to treat conditions such as COPD, diabetes, arthritis, osteoporosis and more.
 
Read more
Hide details
Joe Robinson 08/07/2016 - 17:38 Sign Posted 6 comments
0
0
Votes

Innovation 'Elevator Pitch':
A medical screening technology based on a mathematical model of the autonomic nervous system & physiological systems which has significant potential to improve the cost-effectiveness of primary care
Overview of Innovation:
Strannik technology is based upon a mathematical model of the autonomic nervous system and physiological systems. It meets the key aims and objectives of the EC’s Human Brain Project: (i) to identify what the brain does and how it does it, (ii) to develop a new generation of cognitively-based screening technology, (iii) to understand and adapt with therapeutic effect the multi-level nature of brain function.  This is quite without precedent in modern medicine. The Strannik technology comprises Strannik Virtual Scanning (SVS) and Strannik Light Therapy (SLT). 
The technique can be viewed in a demonstration video at the following link: www.montaguehealthcare.co.uk/presentation.php
SVS is a screening technology which has an unprecedented ability to determine the health of the patient i.e. it is able to determine 5-15 pathologies in each of the 30 main organs (including medical conditions for which the current tests are poor or for which there is currently an unmet clinical need), to differentiate between and quantify the extent of the genotype and phenotype in each pathology, and to determine the earliest onset of each pathology from its presymptomatic origins. The technique adopts a methodology more advanced than is currently used in most diagnostic technologies. It is non-invasive and more safe than contemporary diagnostic tests. The results are available in circa 20 minutes at a cost which is estimated to be 5-10 times lower than contemporary diagnostic tests. It presents the opportunity to screen the entire UK population once (or twice) each year for less than £5BN (est £3-4BN) and to reduce the cost of healthcare by an estimated £20BN pa.
(See Operating Manual: www.montaguehealthcare.co.uk/OperatingManual.pdf)
The basic methodology, and the scope of this technology, is outlined in a series of 60 peer-reviewed medical papers.
(uk.linkedin.com/pub/graham-ewing/44/386/214)
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Strannik Virtual Scanning is able to determine all common pathologies in a single test of 20 minutes duration. In-market surveillance has indicated that SVS appears to be circa 2-23% more precise than contemporary methods of diagnosis. A recent non-clinical study in Spain (10/16) illustrated that the technology was able to determine all known medical conditions in the cohort of (20) patients.
 
Using the data derived from this cognitive, computer-based, test the technique determines the precise parameters of Strannik Light Therapy -which acts upon autonomic dysfunction, and (across a wide range of medical indications) appears to be typically 83-96% effective. This compares with the 50% effectiveness of drugs and also that the effectiveness of many drugs declines over a period.
 
Benefits:
 
  • reduce the flow of patients into the healthcare system;
  • reduce the cost and complexity of training the GP
  • improve the ability of the GP to identify complex medical conditions, reduce the need for repeat consultations, and/or avoid doctor errors
  • reduce the need for histopathology samples (nurses, rubber gloves, sampling tubes, transport costs, histopathology lab costs)
  • reduce expenditure in secondary care i.e. for highly expensive scans and tests;
  • provide health reports and increase the ability for patients to have a clear understanding of their health and assume responsibility for their health i.e. change the focus of medicine  from treating the symptoms to prevention
  • regularly screen the health of the most at-risk patients thereby reducing the need for A&E services
  • improve the accuracy of drug prescribing thereby avoiding mis-prescribing of drugs
  • reduce the need for drugs
  • reduce the overall cost of healthcare by an estimated £20BN pa
“I have to hand it to you. You have correctly and in precise detail identified the five or six major items which are known to be of concern to me”. Dr John Doran, Medical Director, Nottingham’s Queens Medical Center, November 2003.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Support patients to obtain an early diagnosis to seek timely treatment.
Current and planned activity: 
Mimix Montague Healthcare is actively seeking NHS partnerships to move forward Strannik Technology. Evaluation and trials have been conducted in other countries (Russia and Spain) and a collaboration within the UK is currently being sought.
 
  • Procurement / Adoption of Strannick Technology within NHS Trusts
  • Evaluation / Validation / Clinical Trial - Need to gain additional validation seeking a trial centre.
  • Project Assistance required - The Company’s development project is interested in locating possible clinical / academic collaborators.
What is the intellectual property status of your innovation?:
software/copyright
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:
The technology is immediately scaleable. In theory, and as an indication of scaleability, we could train 1000 practitioners to use Strannik technology within 4 weeks. 
Measures:
Strannik Virtual Scanning is unique for a number of very good reasons e.g. (i) that it can determine pathological onset from its presymptomatic origins, (ii) it can determine the full spectrum of pathologies in all organs and not just a single biomarker, (iii) it can determine genotype and phenotype, and (iv) it can determine many conditions where there is currently an unmet clinical need.  Further studies are required to illustrate how such a sophisticated technology will complement the current range of biomarker tests which are generally used in clinical practice. The technique is non-invasive and has a base cost of circa £15/test thereby addressing safety and cost.  The procedure is entirely non-invasive which significantly enhances the patient experience, often experienced as 'a pleasure'.  
Strannik Light Therapy is based upon an understanding of how the brain regulates the autonomic nervous system.  A comparison of Strannik Light Therapy with contemporary methods of treating patients is likely to enhance the patient experience, result in significantly reduced side-effects, and will be at very much lower cost.
Success will be measured by reduced number of patient consultations, lower cost of diagnosing and treating patients. 
Adoption target:
Our aim is to secure the introduction of Strannik technology to every primary care practice
Rejection Reason:
Dear Mr Ewing Thank you very much for your submission to the Meridian Innovation Health Exchange. I can confirm that we have now reviewed your submission and i regret to inform you that we have not been able to identify any clinical champions for this project. While I appreciate that Strannick are looking for support on the evaluation/evidence side, feedback from clinical / academic colleagues has not been positive and therefore we have done everything possible to engage but the appetite isn't there unfortunately. Given that our network is not focussed in exploring this area at this time we will therefore close your idea leaving it visible to our Meridian users. We wish you luck with your innovation. Regards The Meridian Team
Read more
Hide details
Graham Ewing 22/03/2016 - 16:50 Rejected Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
OrthOracle is a multidisciplinary on-line resource comprising a suite of Surgical Atlas’ delivering high definition image based Orthopaedic surgical techniques and educational content for Clinicians, Industry, Academia and Patients
Overview of Innovation:
The training of surgical specialities in the UK has both shortened and is less intense due to the combined effects of a restructured medical training and the European working time directive.
As these influences have been felt over the last decade the resources available to educate both surgeons and the medical workforce have not evolved to account for them. There is far greater requirement to demonstrate continuing education.
 
Allied with this are increased expectations from patients both in terms of their outcomes and level of information available to them to assist in making more informed choices about their healthcare. Increased professional regulation and a requirement to annually demonstrate appropriate levels of professional supporting activities are also areas where a high quality resource delivering validated CPD outcomes has huge potential.
 
Surgery is an inherently visual discipline and the optimal demonstration of its techniques requires the clear illustration of human anatomy as well as it’s adjustment. Existing educational resources do not reflect the interdisciplinary nature of orthopaedic practice nor provide the range or quality of material that is required today.
 
Each Atlas will document the management of a patient from initial assessment through to surgery and then to rehabilitation. Surgical procedures are detailed with high definition images and commentary provided by a Board of senior Consultant Surgeons. Implant technologies for each procedure link directly to industry information.
 
Data is managed to allow different website front ends to be displayed for differing  members of the wider healthcare team and patients. The rich data will support the future development of simulation tools.
 
Boards meet regularly to review new procedures, best practice, patient safety and guidance, medical technologies and research.
 
OrthOracle is not just a digitised text book; it is an interactive web based resource, written by practicing clinicians bringing together the best in clinical practice and orthopaedic technologies covering the entire treatment pathway and facilitates collaboration between clinical, academic and industry sectors leading to improved patient outcomes.

www.footsurgeryatlas.com

The OrthOracle concept has been tested via an early version of The Foot Surgery Atlas, launched in 2007 which, despite no advertising, regularly received over 55,000 hits per month 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
OrthOracle directly support NHS workforce development .
 
The content of OrthOracle is produced by a Board senior practicing surgeons and healthcare professionals, helping to promote and disseminate best practice in all aspects of the healthcare journey.
 
The management of workforce issues such as CPD and revalidation are assisted by the provision of approved and certified educational materials ((ongoing discussions with Royal College of Surgeons (Edinburgh) and other Healthcare regulators and bodies)).
 
A planned secure clinician and patient specific interface for real-time outcome monitoring will assist with safe and optimal patient management.
 
Patient focussed information on their operation, rehabilitation and consent will enable patients to be better informed and prepared for their treatment. This will involve the patient more actively in the process leading to more efficient use of resources and with the aim of improved outcomes.
 
The availability of such a dynamic educational resource 24/7 facilitates training provision, is cost effective and ensures knowledge of procedures is up to date thus ensuring a better informed workforce with improved patient outcomes at all levels of professional practice.
 
Collaboration with QEH Clinical Photography department in developing advanced image capture technologies and protocols.
 
Board meetings regularly bring together NHS clinical consultant with industry to facilitate dialogue on implant development with potential commercial and research spin off benefits for the NHS.
Online Discussion Rating
6.00 (3 ratings)
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
OrthOracle has a global reach. Based in Birmingham with planned events within the Region, supports the Region’s international profile providing a showcase for academic, clinical and industrial skills creating opportunities for the development of new clinical skills, training and product development.
 
It is envisaged that the editors in chief of the 5 additional Surgical Atlas’ (hip, knee, shoulder, spine, hand & wrist) will be recruited from West Midlands Trusts. A number of the additional 25 contributing editors will also be from West Midlands Trusts.
 
  • 6 speciality Boards meeting 3 times per year to be held regularly in West Midlands
  • Unique opportunity for industry to gain regular feedback from Consultant Surgeons
  • Potential for creating global opportunities for West Midlands organisations in new product development, research and training.
  • The multidisciplinary scope of OrthOracle and its high profile internationally active Editorial Boards support the hosting of an annual Digital Orthopaedics Conference which we hope will be based here in the region.
  • In consultation to directly support the proposed Medical Technologies assessment hub
  • OrthOracle creates a global clinical research nexus and hosting opportunity for surgical training, virtual and augmented reality training products and facilities
  • It will also provide Human Factors, User Experience design and multidisciplinary healthcare integration building upon existing world class regional strengths
  • Opportunities for the development and delivery of medical related educational programmes and CPD modules via regional organisations, in association with professional bodies, Royal Colleges and regulating authorities.
  • OrthOracle will immediately create new jobs and support existing employment locally; growing rapidly as additional Surgical Atlas’ and content develops.
  • Look to Developing a global training focus on Orthopaedics here in the West Midlands, building from the position the region has held for many decades in orthopaedics expertise.
 
NOTE: This training platform has the ability to cover a wide range of surgical fields – following the success of Foot & Ankle we will be developing other orthopaedic areas as well as inviting other renowned surgeons to develop their own speciality areas from this foundation.
Current and planned activity: 
Editorial teams members provide Consultant medical services directly and indirectly to the NHS across numerous regions.
 
Clinical photography services of QEH will provide all OrthOracle photography services and project represents a FTE dedicated post. These services are currently being used for the Foot Surgery Atlas.

Planned activities
  • Engage with Health Education England re: workforce development.
  • Seek  Regional surgeons to join Editorial Boards
  • Continue discussions with RCS (Ed) & other AHP bodies, specialist groups and regulating authorities re: partnership, accreditation and CPD
  • Establish a project office
  • Develop a robust marketing strategy/plan
  • Develop sustainable business development strategy/plan
  • Seek Regional participants to assist in evaluating and developing the training delivery process
  • Undertake scoping study re: surgical simulation and augmented reality 
What is the intellectual property status of your innovation?:
OrthOracleTM is a registered Trademark
 
All images in each Surgical Atlas are digitally watermarked and site content monitored to protect from unlicensed data stripping.
 
A policy relating to patient photographs and IP issues applying to all Editorial Board members’ organisations is currently being finalised.
 
A specialist IP legal advisor is retained by Surgical Armoury Ltd to manage should an IP issues arise from the OrthOracle project.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Regional Scalability:
The individual Atlas’ within the OrthOracle and supporting information/services are delivered on-line and so availability is worldwide and at scale.
Additional Orthopaedic surgical specialities will be rolled out as soon as editorial boards are in place using the same procedure capture format. Current plans are for Hip, Knee and Shoulder sections to be undertaken this year as Editors in Chiefs have been identified and are all prominent West Midlands Orthopaedic Surgeons.
Where possible all contributors and service providers will be sourced from within the West Midlands and the project administration centre will be based in Birmingham. There is a pressing need for a Chinese language version and discussions have been held with the head of the West Midlands Chinese business community who is very keen to support the project and a regionally based specialist medical translation service has been identified. 
Measures:
Detailed tracking of website visit statistics will be undertaken and the number and nature of individual visits will be captured and reviewed. Page specific statistics will be interrogated to establish where the page/site design can be refined. Log in data will be collected and generates geographic, organisational, professional and demographic data of the user population. Additional information will be directed to specific groups as appropriate.
Several areas of the site, such as general surgical images and data will be available as a Freemium service, however a stratified subscription model is currently being developed for individual and organisational users who wish to access the wealth of supporting information and services such as the ability to create individual and annotated versions of specific procedures, clinical administration documentation such as patient consent forms, patient guides, access to  research/evidence database, CPD content.
The provision of quality accredited CPD material is a core deliverable of OrthOracle and advanced discussions with The Royal College of Surgeons (Edinburgh) are ongoing with their President, CEO and Head of Education. The College is keen to support this project from their Birmingham offices. Other accreditation and provider bodies have been identified and approached.
A user friendly CPD portal will be created to record individual user CPD in accordance with Professional/regulatory body requirements for audit and revalidation. Each surgical procedure includes specific CPD modules set by the procedure’s submitting surgeon. Individual user access times and interactions can be recorded to facilitate site usage and page viewing metrics.
This education and training platform will be further developed through the development of associated virtual and augmented reality simulators linked to the OrthOracle content (West Midlands partners for the development of these have been identified e.g. Profs Bob Stone and Alan Wing – Bham. Uni)
Adoption target:
Conservative business model assumes global (not WM) registered members numbering 10,000 year 1, 50,000 year 2 & 100-200,000 year 3 (Orig. Atlas had 50,000 users/mth by 2015 without promotion)
Assuming 20% take up by registered users of one or more of the pay-for services the Atlas will be viable midpoint year 2
RCS(Ed) promotion to members not inc
Read more
Hide details
Mark Herron 21/03/2016 - 17:48 Sign Posted Login or Register to post comments
4.3
4
Votes

Innovation 'Elevator Pitch':
The MicroEye system delivers simple, reliable and highly cost-effective continuous glucose, lactate and many other blood analyte samples capable of measurement by stand-alone external diagnostic equipment for display on laptop or bed-head monitor.
Overview of Innovation:
MicroEye transforms point-of-care blood sampling from ‘point in time’ to automated continuous monitoring of a vast range of potential analytes, for improved outcomes in critical care. MicroEye is an easy to use device that is inserted using common peripheral venous catheters. It delivers dialysate to an external sensor system which means the blood can stay in the patient and real-time data is available to standalone monitors, bed head array systems or hospital information systems.

MicroEye is approved for use in the peripheral vascular system and in subcutaneous, intramuscular and adipose tissue. Most small water-soluble molecules can be monitored, and many including glucose and lactate can be monitored in real time, helping to improve clinical outcomes in a range of specialties including intensive care, cardiology, surgery, emergency medicine, paediatrics and neonatology.

Glucose Control
Continuous and automated real-time online monitoring of blood glucose using MicroEye® may provide accurate data for improved management of some patient groups. Although around 10 per cent of intensive care patients may be diabetic, the incidence of stress-induced hyperglycaemia has been reported to range from 30 to 100 per cent. Effective control of blood glucose levels reduces the incidence of hyperglycaemia and hypoglycaemia, both of which may compromise patient safety.
MicroEye delivers real-time blood glucose data which meets ISO 15197 accuracy criteria which results in improved patient outcomes, speedier recovery and shorter hospital stays.
Lactate Monitoring
MicroEye® can be used to assess metabolic stress by monitoring blood lactate levels. High blood lactate (hyperlactatemia) is frequently found in critically ill patients and often used as a marker of adverse outcome. A study* looking at all adult ICU admissions (n=13,932) in a healthcare institution over a three-year period found incidences of high blood lactate between 40 and 45 per cent. There was also a highly significant association between hyperlactatemia (blood lactate > 2 mmol/L) and mortality rates of 27 per cent. Other studies show that mortality rates of nearly 70 per cent are independently associated with blood lactate levels of at least 3.5 mmol/L.

MicroEye gives a reliable measure of cellular hypoxia and can help assess the effectiveness of therapeutic interventions. This data can then be used to improve patient outcomes and allow for a speedier recovery
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
  • Cost saving benefit through better glucose monitoring which has been proven to  improve patient well being resulting in shorter hospital stays
  • Automated continuous monitoring freeing up nurses and other staff to perform other essential tasks, which improves efficiency and ultimately provides a cost saving benefit to the NHS
  • Published work shows an improvement in patient outcome and cost savings from continuous Glycaemic control
  • Trend data can be displayed rather than point in time
  • Compares favourably in cost to current methods.
  • Many other analytes can be collected at the same time and measured offline  e.g. antibiotics
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Our  innovation will bring benefits to patients using the technology as soon as it we have finalised trials and able to bring to market. Thus during this development and the final marketing of this product it will help us secure the growth and develmpent of the company as well as it products, current and futurre

We also are looking forward to developing collaborations and stronger relationships with West Midlands NHS Clinical reseach teams to enhance one anothers research and the care we can deliver to patients.

Some of the lactate research has been conducted at the University of Coventry
Current and planned activity: 
  • Seeking NHS Evaluation Centres / collaborators - We plan to commence evaluations in NHS centres, if possible here in the West Midlands
     
  • Gaining Evaluation and Validation - The device is in final evaluation stage, although it is CE marked for use in EU hospitals
     
  • Developing Final Products & Sales - Following this we will moving through to mass production and growing our sales base from our offices in Coventry and developing exports to countries that have been showing interest.
     
  • Note: To early to say ROI - Value or Time Scale but we suspect thes will be very favourable and beneficial to the NHS and patients.
What is the intellectual property status of your innovation?:
Patented product and IP held by company. Licenced out IP to be used to integrate with other products abroad (Japan and Italy).

Curent Certification:CE marked product, ISO 13485, Directive 93/42/EEC
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Regional Scalability:

We have already conducted feasability studies with our manufacturer to ensure volume production is possible

Measures:

Initially we are looking for user evaluations. We already know the device works succesfully. A full trial protocal is avilable in request

Adoption target:

initially we would lie to start eavuations in 1 -3 centres.

Read more
Hide details
Neil Smith 01/03/2016 - 15:03 Detailed Submission Login or Register to post comments
3.8
5
Votes
-99999
Innovation 'Elevator Pitch':
Clinical CARPS improves patient care outcomes & staff experience through effective management, distribution & prioritisation of work
#Clear, consistent, flexible task allocation
#Real-time workload understanding
#Data for analysis & improvements
Overview of Innovation:
Clinical CARPS (C-CARPS) is a simple to use clinical task management system. Users have been delighted with the speed of implementation & the ability to fine tune the system to their needs
The system improves patient care outcomes & the experience of clinical staff in a very cost effective manner by saving time, optimising the deployment of staff resources & identifying areas for improvement. 
C-CARPS has been implemented with great success by the Hospital at Night team at The Alfred Hospital, Melbourne with our co-developer partners, InControl Australia. Alfred Health have cited many achievements facilitated or directly enabled by the system:
  • improved performance against patient care targets e.g. 8% increase in emergency patients admitted within 4 hours
  • increased overall productivity
  • improved staff attitude towards the overnight shift
Alfred Health won the “The Premier’s Award for Advancing Healthcare 2013”  & "The Metropolitan Health Workforce Initiative Award 2014" for their achievements, in which C-CARPS was instrumental.
C-CARPS replaces the existing method of task allocation, typically reliant on paging & phone calls between staff to clarify patient needs. In simple terms it is used as follows:
  • Nursing staff issue clinical task requests from ward PC’s or mobile devices
  • Team members carry a mobile device to track, manage & update allocated tasks
  • “Clinical Leads” have the ability to re-allocate work according to demand
  • Handovers are managed quickly & safely through the system
Task requests contain all the information required to immediately prioritise & complete the task. Geographic, nurse & patient identifiers provided by C-CARPS task requests optimise efficient task allocation, improve communication & help prevent errors
The ‘Clinical Lead’ can see all tasks in real time and redistribute them as appropriate. This allows free staff to ease the burden on others, preventing individuals from being overwhelmed & minimising delays. Clinical Leads now redistribute around 14% of the work on a nightly basis.
Data from C-CARPS is used to identify long trends & to understand the type of work carried out by specific staff at night. This has provided supporting evidence in cases of complaints or concerns from staff & enabled the implementation of organisational or procedural change to improve staff utilisation & patient care. In one instance, C-CARPS data was used to reduce the overnight drug chart re-writes average of 42 to 2.5
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
  • Saves nursing and clinical staff time by communicating task information in a clear, complete and standardised way, giving staff more time to focus on the tasks themselves and to progress patient care and professional development
  • Clear visibility of entire workload means that teams can respond dynamically in busy periods by re-allocating work to optimise use of valuable resources in real-time
  • A more responsive and even workload distribution ultimately results in fewer delays and reduced risk of clinical errors due to unmanageable workloads, stress levels or ‘burn-out’
  • Improved handover between shifts, saving time and reducing the likelihood of errors
  • Transparency of the system promotes a team ethic and a shared workload mentality
  • The centralised, time-stamped and easily accessible data will save time reporting on:
    •  Performance, creating new opportunities for performance analysis, promote continuous improvement of working practices and monitor any changes.
    • Resolve any complaints or disputes easily by reviewing real time data evidence.
Additional Information
Please watch the presentation “Data to Transform: Electronic Task Management in the After Hours” by Alfred Health’s Benjamin Warren (Redesigning Care Project Officer at Alfred Health) and Dr Kyle Brooks (Senior ICU Registrar and overnight Clinical Lead at The Alfred), available through the InControl Australia YouTube Channel:

https://youtu.be/NmHE0Jg4DXU

Please view the presentation slides, including graphs, from a presentation delivered by Andrew Stripp, Deputy Chief Executive & Chief Operating Officer of Alfred Health, at the 2014 Emergency Department Management Conference in Melbourne, Australia, which demonstrate the instrumental role Clinical CARPS has played in the success of Alfred Health’s ambitious and award winning “Timely Quality Care” initiative:
http://www.slideshare.net/informaoz/andrew-stripp-alfred-health

InControl Australia have produced a short demonstration video entitled “CARPS Clinical Task Management Overview”, showing the basics of task allocation and distribution between the controller PC software and an Android smart device:
https://youtu.be/3a9yaZ1z8L0

 
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Clinical CARPS is a tool that enables safer, more efficient working practices and improved opportunities for performance analysis, facilitating the implementation of further improvements. This can reduce the costs associated with care delivery and dealing with errors and delays.
  • Saves nursing and clinical staff time
  • Allows staff to progress patient care and professional development
  • Provides clear visibility of entire workload to optimise use of valuable resources in real-time
  • A result of workload distribution  is fewer delays and reduced risk of clinical errors  by managing workloads and stress levels and avoiding ‘burn-out’
  • Reducing the likelihood of errors via Improved handover between shifts and saving time
  • Transparency of the system promotes a team ethic and a shared workload mentality
  • Time-stamped and easily accessible data reporting:
    •  new opportunities for performance analysis to promote continuous improvement of working practices whilst monitoring any changes.
    • Easily resolve any concerns, complaints or disputes by reviewing real time data evidence.
 
ROI
  • The potential exists for very high return on investment, depending on the relative efficiency of the hospital’s existing processes. A user of the original CARPS system cited recovering the original investment every four months! The non-clinical version of CARPS typically recovers initial investment within 18 months. We are awaiting analysis of data on installed versions of Clinical CARPS. We are expecting similar or even better results, due to potential cost savings within a clinical environment.

    Note: Our previous model is used successfully within 15 UK NHS trusts to mange non-clinical tasks
Current and planned activity: 
Currently ‘Clinical CARPS’, Clinical Task Management System is being used in Australia and seeking first adoption within the NHS in the UK. We are looking to NHS organisations within the West Midlands to discuss the possibility of adopting the clinical version on a trial-to-permanent basis.
 
We are seeking collaborations with West Midlands NHS trusts, clinical speciality services or an NHS region to experience our technology, understand the simplicity of installation and to witness the benefits that it can bring to managing the clinical workload, especially out of hours where resources may be limited or stretched and thus not immediately available unless the work flow is adjusted. 

Evaluation/Validation – We are seeking a trial centre to work with to gain additional evidence & validation of the benefits that our software delivers

We look forward to discussing with West Midlands Clinical Management teams how ‘Clinical CARPS’ can transform their task management processes.

.
What is the intellectual property status of your innovation?:
Clinical CARPS is the property of In Control Pty Ltd, co-developer partners of Purcell Radio Systems Ltd. Purcell Radio Systems Ltd have sole rights for the distibution of Clinical CARPS within the UK and Europe.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Regional Scalability:

All of our solutions are highly scalable and an installation of CARPS software will typically lead to a future expansion of the system within that site or further installations at other sites within the region or company, usually by word of mouth promotion. Pricing for individual software licences will come down where larger systems are purchased within a single contract. Depending on the needs of the client we would expect to have a single installation up and running within 2 - 3 months.

Measures:

Quality: We expect Clinical CARPS to improve the quality of communication regarding clinical task allocation, for instance Clinical CARPS task requests can be configured for required minimum information to be mandatory. We would expect this to be measurable by a reduction in the amount of time spent on task allocation (phone calls, conversations, etc) and an increase in productivity in the undertaking of the clinical tasks themselves (delivering patient care). We would expect the enhanced analytical possibilities enabled by CARPS data capture to result in the identification of improved working processes, which should also be taken into account as measures of the system's success.
Safety: We expect patient care outcomes to improve based on the fact that Clinicians and nursing staff have more time available to deliver care as above and can re-allocate work according to demand, priority, availability and suitability. We expect to see measurable improvements against patient safety targets such as improved performance against the four hour admission target from emergencey and a reduction in errors and delays to patient care. As above, any improvements to patient safety made possible through CARPS enhanced data capture should also be counted.
Cost: Return on investment can be measured against increases in productivity on the front line and relating to time saved on performance analysis and the production of reports performed my clinical Management. We would expect complaints to be reduced and costs around the complaints process should also be factored in. A normal CARPS system would be expected to cover the cost of implementation within 18 months and we might cautiously expect even better results within the clinical environment, due to the increased value of the resources involved.
People: Feedback from users and stakeholders should give evidence of an improved attitude towards the way clinical tasks are managed compared with the preceeding system.

Adoption target:

Minimum viability would be the out-of hours clinical team at one hospital. After confirmation of the system's success, we would hope to expand use to 24/7 and to implement the system at other hospitals within the WM region.

Read more
Hide details
Tom Purcell 18/02/2016 - 12:27 Detailed Submission Login or Register to post comments
3.7
3
Votes
-99999

Recent Activities

Transforming ADHD Care with Objective data from QbTest has been moved from Initial Submission to Publish 3 days 13 hours ago
AposTherapy has been moved from Initial Submission to Publish 3 days 13 hours ago
Patchwork - Award Winning Temporary Staffing Solution has been moved from Initial Submission to Publish 1 week 4 days ago
The Trans-Urethral Catheterisation (TUC) Safety Valve has been moved from Initial Submission to Publish 3 weeks 5 days ago
PREP SHIELD - limb drape for the operating theatre has been moved from Initial Submission to Publish 4 weeks 1 day ago

Active Campaigns